347 related articles for article (PubMed ID: 15383832)
1. Sulpiride in combination with fluvoxamine increases in vivo dopamine release selectively in rat prefrontal cortex.
Ago Y; Nakamura S; Baba A; Matsuda T
Neuropsychopharmacology; 2005 Jan; 30(1):43-51. PubMed ID: 15383832
[TBL] [Abstract][Full Text] [Related]
2. R(+)-8-OH-DPAT, a serotonin(1A) receptor agonist, potentiated S(-)-sulpiride-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens but not striatum.
Ichikawa J; Meltzer HY
J Pharmacol Exp Ther; 1999 Dec; 291(3):1227-32. PubMed ID: 10565846
[TBL] [Abstract][Full Text] [Related]
3. Antidepressant-like effect of coadministration of sulpiride and fluvoxamine in mice.
Ago Y; Harasawa T; Itoh S; Nakamura S; Baba A; Matsuda T
Eur J Pharmacol; 2005 Sep; 520(1-3):86-90. PubMed ID: 16140294
[TBL] [Abstract][Full Text] [Related]
4. In vivo biogenic amine efflux in medial prefrontal cortex with imipramine, fluoxetine, and fluvoxamine.
Jordan S; Kramer GL; Zukas PK; Moeller M; Petty F
Synapse; 1994 Dec; 18(4):294-7. PubMed ID: 7886621
[TBL] [Abstract][Full Text] [Related]
5. 5-HT6 receptor antagonist SB-399885 potentiates haloperidol and risperidone-induced dopamine efflux in the medial prefrontal cortex or hippocampus.
Li Z; Huang M; Prus AJ; Dai J; Meltzer HY
Brain Res; 2007 Feb; 1134(1):70-8. PubMed ID: 17207474
[TBL] [Abstract][Full Text] [Related]
6. ACP-103, a 5-HT2A/2C inverse agonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens.
Li Z; Ichikawa J; Huang M; Prus AJ; Dai J; Meltzer HY
Psychopharmacology (Berl); 2005 Dec; 183(2):144-53. PubMed ID: 16220333
[TBL] [Abstract][Full Text] [Related]
7. In vivo evidence that constitutive activity of serotonin2C receptors in the medial prefrontal cortex participates in the control of dopamine release in the rat nucleus accumbens: differential effects of inverse agonist versus antagonist.
Leggio GM; Cathala A; Neny M; Rouge-Pont F; Drago F; Piazza PV; Spampinato U
J Neurochem; 2009 Oct; 111(2):614-23. PubMed ID: 19702657
[TBL] [Abstract][Full Text] [Related]
8. Synergistic dopamine increase in the rat prefrontal cortex with the combination of quetiapine and fluvoxamine.
Denys D; Klompmakers AA; Westenberg HG
Psychopharmacology (Berl); 2004 Nov; 176(2):195-203. PubMed ID: 15138756
[TBL] [Abstract][Full Text] [Related]
9. Comparison of effects of haloperidol administration on amphetamine-stimulated dopamine release in the rat medial prefrontal cortex and dorsal striatum.
Pehek EA
J Pharmacol Exp Ther; 1999 Apr; 289(1):14-23. PubMed ID: 10086982
[TBL] [Abstract][Full Text] [Related]
10. 5-HT(1A) and 5-HT(2A) receptors minimally contribute to clozapine-induced acetylcholine release in rat medial prefrontal cortex.
Ichikawa J; Dai J; Meltzer HY
Brain Res; 2002 Jun; 939(1-2):34-42. PubMed ID: 12020849
[TBL] [Abstract][Full Text] [Related]
11. In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain.
Bortolozzi A; Díaz-Mataix L; Toth M; Celada P; Artigas F
Psychopharmacology (Berl); 2007 Apr; 191(3):745-58. PubMed ID: 17265076
[TBL] [Abstract][Full Text] [Related]
12. Role of postsynaptic serotonin1A receptors in risperidone-induced increase in acetylcholine release in rat prefrontal cortex.
Sato M; Ago Y; Koda K; Nakamura S; Kawasaki T; Baba A; Matsuda T
Eur J Pharmacol; 2007 Mar; 559(2-3):155-60. PubMed ID: 17258195
[TBL] [Abstract][Full Text] [Related]
13. F15063, a potential antipsychotic with dopamine D(2)/D(3) receptor antagonist and 5-HT(1A) receptor agonist properties: influence on immediate-early gene expression in rat prefrontal cortex and striatum.
Bruins Slot LA; Lestienne F; Grevoz-Barret C; Newman-Tancredi A; Cussac D
Eur J Pharmacol; 2009 Oct; 620(1-3):27-35. PubMed ID: 19695244
[TBL] [Abstract][Full Text] [Related]
14. Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens.
Kuroki T; Meltzer HY; Ichikawa J
J Pharmacol Exp Ther; 1999 Feb; 288(2):774-81. PubMed ID: 9918588
[TBL] [Abstract][Full Text] [Related]
15. SR46349-B, a 5-HT(2A/2C) receptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens.
Bonaccorso S; Meltzer HY; Li Z; Dai J; Alboszta AR; Ichikawa J
Neuropsychopharmacology; 2002 Sep; 27(3):430-41. PubMed ID: 12225700
[TBL] [Abstract][Full Text] [Related]
16. Modulation of dopamine release by striatal 5-HT2C receptors.
Alex KD; Yavanian GJ; McFarlane HG; Pluto CP; Pehek EA
Synapse; 2005 Mar; 55(4):242-51. PubMed ID: 15668911
[TBL] [Abstract][Full Text] [Related]
17. 5-HT(2A) receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner.
Liégeois JF; Ichikawa J; Meltzer HY
Brain Res; 2002 Aug; 947(2):157-65. PubMed ID: 12176156
[TBL] [Abstract][Full Text] [Related]
18. Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain.
Li Z; Ichikawa J; Dai J; Meltzer HY
Eur J Pharmacol; 2004 Jun; 493(1-3):75-83. PubMed ID: 15189766
[TBL] [Abstract][Full Text] [Related]
19. Perospirone, a novel atypical antipsychotic drug, potentiates fluoxetine-induced increases in dopamine levels via multireceptor actions in the rat medial prefrontal cortex.
Yoshino T; Nisijima K; Shioda K; Yui K; Katoh S
Neurosci Lett; 2004 Jun; 364(1):16-21. PubMed ID: 15193747
[TBL] [Abstract][Full Text] [Related]
20. Systemic administration of amperozide, a new atypical antipsychotic drug, preferentially increases dopamine release in the rat medial prefrontal cortex.
Nomikos GG; Iurlo M; Andersson JL; Kimura K; Svensson TH
Psychopharmacology (Berl); 1994 Jun; 115(1-2):147-56. PubMed ID: 7862887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
